Waters Wins FDA Clearance for At-Home HPV Cancer Test
MILFORD, Mass., April 8, 2026 Waters Corporation has announced U.S. FDA clearance for its Onclarity™ HPV Self-Collection Kit, enabling...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
MILFORD, Mass., April 8, 2026 Waters Corporation has announced U.S. FDA clearance for its Onclarity™ HPV Self-Collection Kit, enabling...
FRANKLIN LAKES, N.J., Feb. 9, 2026 — Becton, Dickinson and Company (BD) announced the successful completion of the previously...
Milford, Massachusetts, January 20, 2026 — Waters Corporation, a global leader in analytical instruments, separations technologies, and laboratory software,...
